Cambridge Investment Research Advisors Inc. Purchases 241,447 Shares of Biosig Technologies, Inc. (NASDAQ:BSGM)

Cambridge Investment Research Advisors Inc. lifted its position in Biosig Technologies, Inc. (NASDAQ:BSGM) by 966.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 266,435 shares of the company’s stock after buying an additional 241,447 shares during the period. Cambridge Investment Research Advisors Inc. owned approximately 1.55% of Biosig Technologies worth $160,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. PFG Investments LLC increased its holdings in Biosig Technologies by 43.5% in the 1st quarter. PFG Investments LLC now owns 158,286 shares of the company’s stock worth $95,000 after buying an additional 48,000 shares during the period. Millennium Management LLC purchased a new stake in shares of Biosig Technologies in the fourth quarter valued at approximately $228,000. Integrity Wealth Advisors Inc. acquired a new position in shares of Biosig Technologies during the 4th quarter worth approximately $61,000. Legacy Investment Solutions LLC acquired a new stake in Biosig Technologies in the 4th quarter valued at $5,369,000. Finally, Geode Capital Management LLC purchased a new stake in Biosig Technologies in the 4th quarter worth $143,000. Institutional investors own 7.16% of the company’s stock.

Biosig Technologies Trading Up 4.4%

BSGM stock opened at $5.46 on Tuesday. Biosig Technologies, Inc. has a 12-month low of $0.23 and a 12-month high of $14.11. The business’s 50-day moving average is $5.76 and its 200 day moving average is $2.60.

Biosig Technologies (NASDAQ:BSGM) last announced its quarterly earnings data on Monday, May 19th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.09). Research analysts expect that Biosig Technologies, Inc. will post -0.88 earnings per share for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets lifted their target price on shares of Biosig Technologies from $2.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, June 6th.

Biosig Technologies Profile

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.